Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Disease and Rheumatoid Arthritis: An Update

  • RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Patients with rheumatoid arthritis (RA) suffer significantly increased cardiovascular (CV) morbidity and mortality, when compared with the general population. Both traditional CV risk factors and high levels of systemic inflammation have been linked to the increased CV risk in RA patients, but significant uncertainty remains regarding the mechanisms through which these factors contribute to CV disease (CVD). In addition, ongoing questions remain regarding how best to identify RA patients at high risk for CVD and what primary and secondary prevention strategies are effective at influencing CV outcome. The present review summarizes recent research in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198–200.

    Article  PubMed  Google Scholar 

  2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303–7.

    Article  PubMed  Google Scholar 

  3. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–45.

    Article  PubMed  Google Scholar 

  4. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004;50:3444–9.

    Article  PubMed  Google Scholar 

  5. Gonzalez A, Maradit KH, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64–9.

    Article  PubMed  CAS  Google Scholar 

  6. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31.

    Article  PubMed  CAS  Google Scholar 

  7. Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther. 2011;13:R131.

    Article  PubMed  Google Scholar 

  8. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–32.

    Article  PubMed  Google Scholar 

  9. van Sijl AM, van den Oever I, Peters MJ, Boers M, Dijkmans BA, van Halm VP, et al. Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRE Study. Ann Rheum Dis. 2012;71:341–4.

    Article  PubMed  Google Scholar 

  10. Matsushita K, van der Velde, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.

    Article  PubMed  Google Scholar 

  11. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012;41:535–44.

    Article  PubMed  Google Scholar 

  12. Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50:3450–7.

    Article  PubMed  Google Scholar 

  13. •• Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482–487. In this work, RA patients with lower total and low-density lipoprotein cholesterol levels had increased risk of cardiovascular disease.

    Article  PubMed  CAS  Google Scholar 

  14. Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-Related Mortality RISk (AMORIS) Study. Ann Rheum Dis. 2010;69:1996–2001.

    Article  PubMed  CAS  Google Scholar 

  15. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–23.

    Article  PubMed  Google Scholar 

  16. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010;69:683–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bartels CM, Kind AJ, Thorpe CT, Everett CM, Cook RJ, McBride PE, et al. Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysis. Semin Arthritis Rheum. 2012.

  18. • Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2012. In this Danish registry, RA patients were less likely to receive aspirin, beta blockers, and statins following discharge from the hospital after suffering a first myocardial infarction. Adherence to statins was also lower in RA patients, relative to non-RA patients.

  19. Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol. 2012;39:32–40.

    Article  PubMed  CAS  Google Scholar 

  20. Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford). 2011;50:324–9.

    Article  CAS  Google Scholar 

  21. • De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea-Robles MV, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2011;70:1020–4. Discontinuation of statins in RA patients was associated with a 67 % increased risk of myocardial infarction.

    Article  PubMed  Google Scholar 

  22. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562–71.

    PubMed  CAS  Google Scholar 

  23. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52:3045–53.

    Article  PubMed  Google Scholar 

  24. del Rinco I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 2005;52(11):3413–23.

    Article  Google Scholar 

  25. • Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011. Higher swollen joint counts and higher average C-reactive protein levels were associated with incident as well as progressive carotid plaque in a 158-patient RA cohort followed for 3 years.

  26. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–67.

    Article  PubMed  Google Scholar 

  27. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103:2283–8.

    Article  PubMed  Google Scholar 

  28. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–8.

    Article  PubMed  CAS  Google Scholar 

  29. McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119:1135–45.

    Article  PubMed  CAS  Google Scholar 

  30. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009;60:2870–9.

    Article  PubMed  CAS  Google Scholar 

  31. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009;60:2428–37.

    Article  PubMed  CAS  Google Scholar 

  32. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 1996;37:2473–91.

    PubMed  CAS  Google Scholar 

  33. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495–508.

    PubMed  CAS  Google Scholar 

  34. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41:1481–4.

    PubMed  CAS  Google Scholar 

  35. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005–19.

    Article  PubMed  CAS  Google Scholar 

  36. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774–82.

    Article  PubMed  CAS  Google Scholar 

  37. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152–4.

    Article  PubMed  CAS  Google Scholar 

  38. Khera AV, Cuchel M, de Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.

    Article  PubMed  CAS  Google Scholar 

  39. • Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, Fitzgerald J, Ranganath VK, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012. The cholesterol efflux function of high-density lipoproteins (HDL) was shown to be impaired in RA patients with high disease activity, as compared with low disease activity, and was inversely correlated with levels of systemic inflammation.

  40. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, et al. Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with proinflammatory HDL in rheumatoid arthritis. Arthritis Rheum. 2012.

  41. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.

    Article  PubMed  CAS  Google Scholar 

  42. Huang AL, Vita JA. Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc Med. 2006;16:15–20.

    Article  PubMed  CAS  Google Scholar 

  43. Sidibe A, Mannic T, Arboleas M, Subileau M, Gulino-Debrac D, Bouillet L, et al. Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor alpha-induced VE-cadherin cleavage. Arthritis Rheum. 2012;64:77–87.

    Article  PubMed  CAS  Google Scholar 

  44. Giles JT, Fert-Bober J, Park JK, Bingham III CO, Andrade F, Fox-Talbot K, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012;14:R39.

    Article  PubMed  Google Scholar 

  45. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2009;38:366–71.

    Article  PubMed  Google Scholar 

  46. •• Evans MR, Escalante A, Battafarano DF, Freeman GL, O'Leary DH, del Rincón, I. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum. 2011;63:1211–20. The presence of unilateral carotid plaque was associated with a two and a half 2.5-fold increased risk of acute coronary syndrome in patients with RA, as compared with patients without plaque.

    Article  PubMed  Google Scholar 

  47. Karpouzas G, Naser A, Choi T, Hajsadeghi F, Munoz S, Budoff M. Higher prevalence, extent, and severity of "vulnerable" coronary plaque in asymptomatic patients with rheumatoid arthritis (RA) [Abstract]. Arthritis Rheum. 2010.

  48. Karpouzas G, Malpeso J, Li D, Razaeian P, Peralta M, Munoz S, et al. Differential predictors of mixed and fully calcified coronary plaques in coronary artery disease-naive patients with rheumatoid arthritis [Abstract]. Arthritis Rheuma. 2011.

  49. Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937–42.

    PubMed  CAS  Google Scholar 

  50. Hinkema HJ, Nienhuis HL, de Groot L, Smit AJ, van Roon AM, Bijl M, et al. Is small artery elasticity decreased prior to intima-media thickening in patients with longstanding rheumatoid arthritis? J Rheumatol. 2011;38:2133–40.

    Article  PubMed  Google Scholar 

  51. Chatterjee AM, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum. 2011.

  52. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8:301–26.

    Article  PubMed  CAS  Google Scholar 

  53. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum. 2009;38:372–81.

    Article  PubMed  CAS  Google Scholar 

  54. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842–5.

    Article  PubMed  CAS  Google Scholar 

  55. Jamnitski A, Visman IM, Peters MJ, Dijkmans BA, Voskuyl AE, Nurmohamed MT. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis. 2010;69:1929–33.

    Article  PubMed  CAS  Google Scholar 

  56. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. Arthritis Care Res (Hoboken ). 2012.

  57. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.

    Article  PubMed  CAS  Google Scholar 

  58. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80.

    Article  PubMed  CAS  Google Scholar 

  59. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222–32.

    Article  PubMed  CAS  Google Scholar 

  60. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5:e14328.

    Article  PubMed  CAS  Google Scholar 

  61. Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? a review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis. 2007;66:1132–6.

    Article  PubMed  CAS  Google Scholar 

  62. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38:2169–71.

    Article  PubMed  CAS  Google Scholar 

  63. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis. 2010;69:1342–5.

    Article  PubMed  CAS  Google Scholar 

  64. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertens. 2010;55:333–8.

    Article  CAS  Google Scholar 

  65. Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70:1164–5.

    Article  PubMed  Google Scholar 

  66. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576–82.

    Article  PubMed  Google Scholar 

  67. Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62:3145–53.

    Article  PubMed  Google Scholar 

  68. Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, et al. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res. 2011;157:10–8.

    Article  PubMed  CAS  Google Scholar 

  69. Ljung L, Simard JF, Jacobsson L, Rantapaa-Dahlqvist S, Askling J. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum. 2012;64:42–52.

    Article  PubMed  CAS  Google Scholar 

  70. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905–12.

    Article  PubMed  CAS  Google Scholar 

  71. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518–31.

    Article  CAS  Google Scholar 

  72. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken ). 2011;63:522–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

Dr. Charles-Schoeman is supported by the National Institutes of Health, Grants NHLBI 5K23HL094834 and NIAMS 5R21AR 57913.

Disclosure

Dr. Charles-Schoeman has served as a consultant for Pfizer, has received grant support from Pfizer and Bristol-Myers Squibb, has received honoraria from Pfizer, had travel/accommodations expenses covered/reimbursed by Pfizer, and has served as a co-investigator in clinical trials for Hoffman La Roche.

Author information

Authors and Affiliations

  1. Division of Rheumatology, David Geffen School of Medicine, UCLA, 1000 Veteran Avenue Room 32-59, Los Angeles, CA, 90095-1670, USA

    Christina Charles-Schoeman

Authors
  1. Christina Charles-Schoeman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Charles-Schoeman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Charles-Schoeman, C. Cardiovascular Disease and Rheumatoid Arthritis: An Update. Curr Rheumatol Rep 14, 455–462 (2012). https://doi.org/10.1007/s11926-012-0271-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-012-0271-5

Keywords

Search

Navigation